Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LNA-i-miR-NC
- Development stage
- Unknown
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, Intravenous
01
Overview
LNA-i-miR-NC is a locked nucleic acid (LNA)-based antisense oligonucleotide with a phosphorothioate (PS) modified backbone that serves as a negative control (scrambled sequence) in experiments evaluating the activity of LNA-i-miR-221, an inhibitor targeting miR-221. LNA-i-miR-NC does not target any specific microRNA but replicates the chemical structure of LNA-i-miR-221, allowing for assessment of nonspecific effects of the LNA technology or oligonucleotide chemistry in vitro and in vivo. It is typically administered systemically to animal models as a control alongside the active inhibitor to differentiate between sequence-specific and nonspecific effects of LNA-based therapeutics[2].
- Other names
- LNA-i-miR-NCscrambled oligonucleotide control for LNA-i-miR-221
Beyond the preview
Go deeper on LNA-i-miR-NC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LNA-i-miR-NC.